• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • Navigate Novartis
    • Patients
    • Healthcare Professionals
    • Media
    • Investors
    • Partners
    • ESG
    • Job Seekers
    • Clinical Trials
  • Coronavirus
  • Global
    • Novartis site directory
Novartis logo: a global healthcare company
  • Our Company
    • Our Leadership
      • Board of Directors
      • Executive Committee of Novartis
    • Our Approach
      • Strategy
      • Corporate Responsibility
      • Diversity & Inclusion
      • Partnering
      • People and Culture
    • Our Business
      • Global Product Portfolio
      • Innovative Medicines
      • Novartis Pharmaceuticals
      • Novartis Gene Therapies
      • Novartis Oncology
      • Sandoz
    • Media
      • Newsroom
      • News Archive
      • Multimedia Resources
      • Subscribe to Updates
    • Investors
      • Event Calendar
      • Financial Data
      • Share Data & Analysis
      • Shareholder Information
      • Environmental, Social & Governance
  • Our Focus
    • Disease Areas
      • Cancer
      • Cardiovascular, Renal & Metabolism
      • Immunology & Dermatology
      • Ophthalmology
      • Neuroscience
      • Respiratory
    • Platforms and Technology
      • Data and Digital
      • Cell & Gene Therapy
    • Novartis Stories
      • Discovery
      • From Our Labs
      • Access to Healthcare
      • Patient Perspectives
      • People and Culture
      • Live Magazine
  • Our Impact
    • Building Trust with Society
      • Corporate Responsibility
      • Ethical Standards
      • Access
      • Environmental Sustainability
    • Global Health
      • Malaria
      • Sickle Cell Disease
      • Chagas disease
      • Leprosy
      • Novartis Foundation
    • ESG Performance and Reporting
      • Materiality
      • Environmental, Social and Governance
      • Transparency and Disclosures
      • Positions on Key Topics
      • Statements on Key Issues
  • Our Science
    • Research & Early Development
      • Novartis Institutes for BioMedical Research
      • Research Disease Areas
      • Postdoc Program
      • Open Source Science
    • Drug Development at Novartis
      • Novartis Pipeline
      • Clinical Trials
      • Translational Medicine
      • Global Product Portfolio
    • Science Stories
      • Discovery
      • From Our Labs
  • Careers
    • Your Career
      • Global Career Search
      • Teams and Skills
      • Gene Therapies Careers
    • Working at Novartis
      • Diversity & Inclusion
      • Corporate Responsibility
    • Career Programs
      • Our Career Programs
      • Students and Scholars
      • Novartis Quantitative Sciences Hackathon
Search
Rebuilding blood
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
    • Whatsapp
  • Jump to Comments
Stories/From Our Labs

Rebuilding blood

Why are some sickle cell disease patients protected from the disease? Learn about our biomedical research in the field.

Jan 06, 2015

It was a medical mystery. The patients should be showing symptoms of sickle cell anemia. They harbored dangerous mutations in the gene for hemoglobin, the protein in red blood cells that carries oxygen. But they were relatively healthy. Why were they protected from the devastating disease?

Academic groups around the world launched an investigation and made an interesting discovery. Most of us stop producing the fetal form of hemoglobin—to which oxygen is highly attracted—soon after birth. The unexpectedly healthy patients, however, keep making fetal hemoglobin, thereby compensating for the defective adult form of the protein.

Researchers at Novartis and the biotech company Intellia Therapeutics would like to switch the gene for fetal hemoglobin back on in those suffering from sickle cell anemia. The team hopes to extract red blood cells from patients, edit their DNA—using technology called CRISPR—to flip the switch, and then inject the revised cells back into the body. At this point, the project is in its infancy.

“Human data are driving our therapeutic strategy for hematological disorders,” says Lloyd Klickstein, head of translational medicine for the New Indications Discovery Unit at the Novartis Institutes for BioMedical Research. “We know that the fetal form of hemoglobin modifies the course of sickle cell anemia, so we’re optimistic about this potential gene therapy.”

The team also is looking beyond sickle cell anemia to other hematological applications of gene editing. An experimental treatment by Novartis called HSC835 potentially expands the possibilities.

In some cases, it will be difficult to safely obtain enough blood cells from a patient to make editing feasible, especially if he or she needs frequent blood transfusions to stay alive. HSC835 is designed to multiply blood stem cells, which give rise to all the other cells of the blood. It might be possible to combine gene editing with HSC835 outside the body when the supply of blood cells from a particular patient—or group of patients—is limited.

Media Inquiries: Jeff Lockwood +1 617 871 7026

Tags: 
Novartis Institutes for BioMedical Research
    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
      • Whatsapp
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

Coronavirus
From Our Labs

A visual tour of scientific strategies for combating coronavirus

Wendi Yajnik, Global Head of Academic Partnerships and External Innovation for research
From Our Labs

Advancing medicine through collaboration

Special instrument controlled by a production associate
From Our Labs

Turning the power of nuclear technology into a medical force

You are here

  1. Home ›
  2. Stories ›
  3. From Our Labs

Novartis Global

  • Navigate Novartis

    • Patients & Caregivers
    • Healthcare Professionals
    • Investors
    • Media
    • Society & ESG
    • Partners
  • Contact Us

    • Global Contacts
    • Office Locations
    • For Investors
    • For Media
  • About Novartis

    • Our Company
    • Our Focus
    • Our Impact
    • Our Science
    • Our Stories
  • Our Portfolio

    • Global Product Portfolio
    • Global Clinical Pipeline
  • Careers

    • Career Search

Connect with Novartis

  • twitter
  • linkedin
  • youtube
  • facebook
  • instagram
Novartis Site Directory
© 2021 Novartis AG
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Site Map
  • Cookie Settings

This site is intended for a global audience.